secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001437749-26-007422
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences renames to Filana Therapeutics; new ticker FLNA effective March 11
--------------------------------------------------------------------------------

- Company changed legal name to Filana Therapeutics, Inc. effective March 10, 2026.
- Common stock begins trading on Nasdaq under ticker FLNA on March 11, 2026.
- New name reflects strategic focus on modulating filamin A protein for CNS disorders like TSC-related epilepsy.
- Amended bylaws modernize provisions for meetings, advance notice, director terms, and uncertificated shares.
- No changes to restated certificate of incorporation beyond the name change.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774926007422/0001437749-26-007422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774926007422/sava20260307_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-007422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer